Search research articles
Contact Us
Filters
Showing results (71-80 of 130) with videos related to
Page
of 13
Sort By:
Nature Medicine
|
October 1, 2024
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Binghe Xu, Shusen Wang, Min Yan, et al.
Journal of Breast Cancer
|
October 4, 2017
Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
Seeyoun Lee, In Hae Park, Seho Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research : BCR
|
January 12, 2023
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>-</sup>-Advanced Breast Cancer
Patrick Neven, Stephen R D Johnston, Masakazu Toi, et al.
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
The New England Journal of Medicine
|
September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Aditya Bardia, Xichun Hu, Rebecca Dent, et al.
JCO Precision Oncology
|
September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
Cancer Research and Treatment
|
March 21, 2020
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 130) with videos related to
Sort By:
Page
of 13
Nature Medicine
|
October 1, 2024
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Binghe Xu, Shusen Wang, Min Yan, et al.
Journal of Breast Cancer
|
October 4, 2017
Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
Seeyoun Lee, In Hae Park, Seho Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research : BCR
|
January 12, 2023
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>-</sup>-Advanced Breast Cancer
Patrick Neven, Stephen R D Johnston, Masakazu Toi, et al.
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
The New England Journal of Medicine
|
September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Aditya Bardia, Xichun Hu, Rebecca Dent, et al.
JCO Precision Oncology
|
September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
Cancer Research and Treatment
|
March 21, 2020
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, et al.
Page
of 13